Source:http://linkedlifedata.com/resource/pubmed/id/15806128
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2005-5-4
|
| pubmed:abstractText |
A total of 40 patients with relapsed/refractory Hodgkin's disease (HD) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) from an HLA-identical sibling (n=20) or a matched unrelated donor (n=20). The median age was 31 years (range 18-58). Disease status at allo-SCT was refractory relapse (n=14) or sensitive relapse (n=26). The conditioning regimens were fludarabine-cyclophosphamide+/-antithymocyte globulin (n=14), a less intensive regimen, and fludarabine-melphalan (FM) (n=26), a more intensive one. The two groups had similar prognostic factors. The median time to neutrophil recovery (ie absolute neutrophil count >/=500/microl) was 12 days (range 10-24). The median time to platelet recovery (ie platelet count >/=20 000/microl) was 17 days (range 7-132). Day 100 and cumulative (18-month) transplant-related mortalities (TRMs) were 5 and 22%. Twenty-four patients (60%) are alive (14 in complete remission or complete remission, unconfirmed/uncertain) with a median follow-up of 13 months (4-78). In all, 16 patients expired (TRM n=8, disease progression n=8). FM patients had better overall survival (73 vs 39% at 18 months; P=0.03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P=0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:AcholonuSS,
pubmed-author:AnderliniPP,
pubmed-author:AnderssonBB,
pubmed-author:ChamplinR ERE,
pubmed-author:CohenAA,
pubmed-author:De LimaMM,
pubmed-author:DonatiGG,
pubmed-author:FayadLL,
pubmed-author:GiraltSS,
pubmed-author:GozBB,
pubmed-author:HosinoKK,
pubmed-author:IppolitoEE,
pubmed-author:KhouriII,
pubmed-author:OkorojiG-JGJ,
pubmed-author:ProBB,
pubmed-author:RodriguezM AMA,
pubmed-author:RomagueraJJ,
pubmed-author:SalibaRR,
pubmed-author:UenoN TNT,
pubmed-author:YounesAA
|
| pubmed:issnType |
Print
|
| pubmed:volume |
35
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
943-51
|
| pubmed:meshHeading |
pubmed-meshheading:15806128-Adolescent,
pubmed-meshheading:15806128-Adult,
pubmed-meshheading:15806128-Female,
pubmed-meshheading:15806128-Graft vs Host Disease,
pubmed-meshheading:15806128-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:15806128-Hodgkin Disease,
pubmed-meshheading:15806128-Humans,
pubmed-meshheading:15806128-Leukocyte Transfusion,
pubmed-meshheading:15806128-Male,
pubmed-meshheading:15806128-Middle Aged,
pubmed-meshheading:15806128-Transplantation, Homologous,
pubmed-meshheading:15806128-Transplantation Conditioning
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen.
|
| pubmed:affiliation |
Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. panderli@mdanderson.org
|
| pubmed:publicationType |
Journal Article
|